Uniform field controlled magnetic cell targeting to stents
均匀场控制的磁性细胞靶向支架
基本信息
- 批准号:8625329
- 负责人:
- 金额:$ 41.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-16 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAftercareAngioplastyAnimalsArterial InjuryArteriesAutologousBiological AssayBioluminescenceBlood VesselsCell LineCell ProliferationCell SurvivalCellsCharacteristicsCultured CellsDoseDrug FormulationsDrug or chemical Tissue DistributionEndothelial CellsEnergy TransferFamily suidaeFirefly LuciferasesGenerationsGrowthHealedHomingImageIn VitroKineticsLabelLuciferasesMagnetismMeasurementMeasuresMediatingMethodologyMethodsModelingModificationPatientsPolymersPrecipitationProceduresProcessPropertyPublicationsRattusRelative (related person)ReporterResearchSchemeSiteStenosisStentsTechniquesTherapeuticTherapeutic EffectToxic effectVascular Diseasesbasebiomaterial compatibilitycomputerizedhealingimplantationin vivoin vivo Modelinjuredinnovationluminescencemorphometrynanoparticlenovelparticlephysical propertypreventprogramsrepairedresearch studyrestenosistargeted deliveryuptake
项目摘要
DESCRIPTION (provided by applicant): The proposed research will explore the hypothesis that magnetically guided targeting of endothelial cells (EC) to stented arteries can reduce vessel reocclusion (restenosis) following stent angioplasty. Re-endothelialization oriented strategies have potential to prevent restenosis while avoiding the side effects of the currently used therapies. However, in order to fully realize this potential a significant improvement in cell delivery efficiency is required. This study will investigate two novel ideas: 1) the application of
magnetic nanoparticles (MNP) for providing EC with magnetic responsiveness adequate for their targeted delivery to stented arteries; and 2) using a uniform field-controlled magnetic targeting of EC to reversibly magnetizable stents for enhanced reendothelialization and inhibition of restenosis post stenting. The present studies will address the following specific aims: AIM 1: MNP characterization with respect to their physical properties, cell compatibility, uptake and degradation kinetics. Biodegradable fluorescent-labeled MNP will be formulated using a modification of the polymer precipitation approach. The size, composition and magnetic properties of MNP will be characterized, and their cell compatibility, internalization and degradation kinetics will be the main endpoints of the Aim 1 experiments. The magnetic responsiveness of MNP and EC treated with MNP will be measured by alternating gradient magnetometer. The kinetic studies will be performed in cultured cells using fluorimetry and global FQrster Resonance Energy Transfer measurements. Cell compatibility of MNP will be determined using fluorimetric cell toxicity assays. AIM 2: EC targeting and reendothelialization studies. Arterial localization and tissue distribution after magnetic vs. non- magnetic delivery of
MNP-impregnated EC stably expressing firefly luciferase will be studied by in vivo bioluminescence and luminometry, respectively, in the rat carotid stenting model. The local kinetic profiles of stent-targeted cells will be compared 1, 7 and 28 days post treatment with endothelialization determined using a quantitative immunohistochemical strategy. AIM 3: antirestenotic efficacy of targeted EC. The extent of restenosis in animals treated under magnetic conditions with MNP-loaded EC will be determined by computerized morphometry and compared that in non-magnetic delivery and 'stenting only' controls four weeks post delivery.
描述(由申请人提供):拟议的研究将探讨以下假设:磁引导内皮细胞(EC)靶向支架动脉可以减少支架血管成形术后血管再闭塞(再狭窄)。以再内皮化为导向的策略有可能预防再狭窄,同时避免当前使用的疗法的副作用。然而,为了充分实现这一潜力,需要显着提高细胞递送效率。本研究将研究两个新颖的想法:1)应用
磁性纳米粒子(MNP),用于为 EC 提供足够的磁响应能力,以将其定向输送到支架动脉; 2) 使用均匀场控制的 EC 磁性靶向可逆磁化支架,以增强再内皮化并抑制支架置入后的再狭窄。目前的研究将解决以下具体目标: 目标 1:MNP 的物理特性、细胞相容性、摄取和降解动力学表征。可生物降解的荧光标记 MNP 将使用聚合物沉淀方法的改进来配制。 MNP 的尺寸、组成和磁性将被表征,其细胞相容性、内化和降解动力学将成为 Aim 1 实验的主要终点。将通过交替梯度磁力计测量MNP和经MNP处理的EC的磁响应性。动力学研究将使用荧光测定法和全局 FQrster 共振能量转移测量在培养细胞中进行。 MNP 的细胞相容性将通过荧光细胞毒性测定来确定。目标 2:EC 靶向和再内皮化研究。磁性与非磁性输送后的动脉定位和组织分布
将在大鼠颈动脉支架模型中分别通过体内生物发光和发光测定法研究稳定表达萤火虫荧光素酶的 MNP 浸渍 EC。支架靶向细胞的局部动力学特征将在治疗后 1、7 和 28 天与使用定量免疫组织化学策略测定的内皮化进行比较。目标 3:靶向 EC 的抗再狭窄功效。在磁性条件下用负载 MNP 的 EC 治疗的动物的再狭窄程度将通过计算机形态测定法确定,并在分娩后 4 周比较非磁性输送和“仅支架”对照中的再狭窄程度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Chorny其他文献
Michael Chorny的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Chorny', 18)}}的其他基金
Multimeric prodrugs for pulmonary hypertension therapy
用于肺动脉高压治疗的多聚体前药
- 批准号:
10475200 - 财政年份:2021
- 资助金额:
$ 41.04万 - 项目类别:
Multimeric prodrugs for pulmonary hypertension therapy
用于肺动脉高压治疗的多聚体前药
- 批准号:
10287001 - 财政年份:2021
- 资助金额:
$ 41.04万 - 项目类别:
Local Control of endochondral ossification by retinoid-loaded nano-particles
类视黄醇纳米颗粒对软骨内骨化的局部控制
- 批准号:
10238000 - 财政年份:2018
- 资助金额:
$ 41.04万 - 项目类别:
Local Control of endochondral ossification by retinoid-loaded nano-particles
类视黄醇纳米颗粒对软骨内骨化的局部控制
- 批准号:
10472544 - 财政年份:2018
- 资助金额:
$ 41.04万 - 项目类别:
Integrated drug-in-cell therapy of in-stent restenosis
支架内再狭窄的综合药物细胞治疗
- 批准号:
9256528 - 财政年份:2016
- 资助金额:
$ 41.04万 - 项目类别:
Uniform field controlled magnetic cell targeting to stents
均匀场控制的磁性细胞靶向支架
- 批准号:
9024605 - 财政年份:2012
- 资助金额:
$ 41.04万 - 项目类别:
Uniform field controlled magnetic cell targeting to stents
均匀场控制的磁性细胞靶向支架
- 批准号:
8806592 - 财政年份:2012
- 资助金额:
$ 41.04万 - 项目类别:
Uniform field controlled magnetic cell targeting to stents
均匀场控制的磁性细胞靶向支架
- 批准号:
8305243 - 财政年份:2012
- 资助金额:
$ 41.04万 - 项目类别:
Uniform field controlled magnetic cell targeting to stents
均匀场控制的磁性细胞靶向支架
- 批准号:
8459382 - 财政年份:2012
- 资助金额:
$ 41.04万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
减少年轻成年睾丸癌幸存者不良后果的生物行为干预
- 批准号:
10736501 - 财政年份:2023
- 资助金额:
$ 41.04万 - 项目类别:
The development of a technology-based information support intervention (iSupport) among patients with differentiated thyroid cancer post radioactive iodine therapy
针对放射性碘治疗后分化型甲状腺癌患者开发基于技术的信息支持干预 (iSupport)
- 批准号:
10581121 - 财政年份:2023
- 资助金额:
$ 41.04万 - 项目类别:
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
多域肽水凝胶作为癌症治疗的治疗传递平台
- 批准号:
10743144 - 财政年份:2023
- 资助金额:
$ 41.04万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 41.04万 - 项目类别:
PA TH2Caregiving: Data-Driven Digital Engagement to Assess and Address the Needs of Family Caregivers
PA TH2Caregiving:数据驱动的数字参与,评估和满足家庭护理人员的需求
- 批准号:
10598028 - 财政年份:2023
- 资助金额:
$ 41.04万 - 项目类别: